COMPARATIVE ANALYSIS OF HEPATOPROTECTIVE PROPERTIES OF GLIFLOZINS IN PATIENTS WITH TYPE 2 DIABETES AND NONALCOHOLIC STEATOHEPATITIS
Abstract
Introduction. Type 2 diabetes (T2D) and non-alcoholic steatohepatitis (NASH) are considered by world experts to be global non-communicable epidemics. Undoubtedly, the main aim of the medical community is to develop patient-centred principles for the treatment of people with comorbidities. The aim of the study was to evaluate the hepatoprotective properties of glyflozins.
Methods. We examined 54 patients with T2D and NASH, who were divided into three study groups: Group I (n=18) received basic medical therapy (BMT): metformin – 2000 mg/day, alpha-lipoic acid – 600 mg/day, rosuvastatin – 10 mg/day; group II (n=18) used BMT in combination with dapagliflozin at a daily dose of 10 mg and group III (n=18) received 10–25 mg/day of empagliflozin. The study period lasted 12 weeks.
Results. After 12 weeks of treatment with dapagliflozin/ empagliflozin as part of BMT promotes more than a twofold reduction in the biomarker of liver fibrosis (II, III groups: FIB-4: ∆‑34.50%, ∆‑35.10%, p<0.001, respectively), while in patients of I group this index decreased by 22.44%. A significant reduction in the liver fibrosis (HEPAmet) was confirmed in patients of II groups (∆‑81.09%, p<0.001) and III (∆‑76.62%, p<0.01). The findings of shear wave elastography of the liver indicate that in patients of II group a significant decrease in liver parenchymal stiffness by 10.73% (p<0.001), in group III – by 13.97% (p<0.001), while in patients of group I a positive trend was found without statistically significant changes (∆‑3.39%, p>0.05).
Conclusions. Glyflozins demonstrate an alternative hepatocentric approach to achieving compensation of carbohydrate and lipid metabolism. After 12 weeks of BMT in combination with dapagliflozin/empagliflozin contributes to a significant reduction in markers of liver fibrosis with a tendency to reduce liver stiffness according to the METAVIR scale.
Downloads
References
Fadieienko HD, Kolesnikova OV. Komorbidnist neinfektsiinykh zakhvoriuvan [kerivnytstvo dlia likariv]. Kharkiv: TOV «Dim Reklamy» Publ., 2020. 212 p.
Younossi ZM, Golabi P, Price JK, Owrangi S, et al. The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes. Clin Gastroenterol Hepatol. 2024; 22(10): 1999-2010.e8. https://doi.org/10.1016/j.cgh.2024.03.006
Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022; 10 (4): 284-296. https://doi.org/10.1016/S2213-8587(22)00003-1
Harrison SA, Allen AM, Dubourg J, Noureddin M, et al. Challenges and opportunities in NASH drug development. Nat Med. 2023; 29 (3): 562-573. https://doi.org/10.1038/s41591-023-02242-6
Lombardi R, Mantovani A, Cespiati A, Francione P, et al. Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors. Dig Liver Dis. 2024; 56 (4): 551-558. https://doi.org/10.1016/j.dld.2023.09.023
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023; 77(5): 1797-1835. https://doi.org/10.1097/HEP.0000000000000323
Ajmera V, Tesfai K, Sandoval E, Lopez S, et al. Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes. Hepatology. 2024; 79 (5): 1098-1106. https://doi.org/10.1097/HEP.0000000000000635
Gupta U, Ruli T, Buttar D, Shoreibah M, et al. Metabolic dysfunction associated steatotic liver disease: Current practice, screening guidelines and management in the primary care setting. Am J Med Sci. 2024; 367 (2): 77-88. https://doi.org/10.1016/j.amjms.2023.11.007
Symvoulakis E, Tsiligianni I. Practice Recommendations for the Management of MASLD in Primary Care: Consensus Results. Diseases. 2024;12(8):180. https://doi.org/10.3390/diseases12080180
Nuffield Department of Population Health Renal Studies Group. SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022; 400 (10365): 1788-1801. https://doi.org/10.1016/S0140-6736(22)02074-8
Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022; 400 (10354): 757-767. https://doi.org/10.1016/S0140-6736(22)01429-5
Patel SM, Kang YM, Im K, Neuen BL, et al. Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis. Circulation. 2024; 149(23):1789-1801. https://doi.org/10.1161/CIRCULATIONAHA.124.069568
Engström A, Söderling J, Hviid A, Eliasson B, et al. Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study. Eur Heart J Cardiovasc Pharmacother. 2024; 10 (5): 432-443. https://doi.org/10.1093/ehjcvp/pvae045
Bica IC, Pietroșel VA, Salmen T, Diaconu CT, et al. The Effects of Cardioprotective Antidiabetic Therapy on Microbiota in Patients with Type 2 Diabetes Mellitus-A Systematic Review. Int J Mol Sci. 2023; 24 (8): 7184. https://doi.org/10.3390/ijms24087184
Jiang Y, Yang J, Xia L, Wei T, et al. Gut Microbiota-Tryptophan Metabolism-GLP-1 Axis Participates in β-Cell Regeneration Induced by Dapagliflozin. Diabetes. 2024; 73 (6): 926-940. https://doi.org/10.2337/db23-0553
Liao L, Wang T, Zhang L, Wei Y, et al. Protective Mechanisms of SGLTi in Ischemic Heart Disease. J Cardiovasc Transl Res. 2024; 17(5):1018-1035. https://doi.org/10.1007/s12265-024-10513-x
Patoulias D, Kassimis G, Fragakis N. Sodium-glucose co-transporter-2 inhibitors, gut microbiota, and atherosclerotic cardiovascular disease: Another mountain to conquer? Pharmacol Res. 2023; 187:106619. https://doi.org/10.1016/j.phrs.2022.106619
Gholami M, Coleman-Fuller N, Salehirad M, Darbeheshti S, et al. Neuroprotective Effects of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors (Gliflozins) on Diabetes-Induced Neurodegeneration and Neurotoxicity: A Graphical Review. Int J Prev Med. 2024; 15: 28. https://doi.org/10.4103/ijpvm.ijpvm_5_23
Omari MB, Naseri S, Hassan AJ. Drug Safety Evaluation of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Comorbid Patients by Review of Systemic Extraglycemic Effects. Diabetes Metab Syndr Obes. 2024; 17:1131-1141. https://doi.org/10.2147/DMSO.S448670
Shakour N, Karami S, Iranshahi M, Butler AE, et al. Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review. Diabetes Metab Syndr. 2024;18(1):102934. https://doi.org/10.1016/j.dsx.2023.102934
Elektronnyj dokument «Klinichna nastanova, zasnovana na dokazah «Cukrovyj diabet», 2024 rik, available at: https://www.dec.gov.ua/cat_mtd/galuzevi-standarti-ta-klinichni-nastanovi/.
American Diabetes Association Professional Practice Committee; 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care. 2024; 47 (1): S20–S42. https://doi.org/10.2337/dc24-S002
Diniz MFHS, Beleigoli AMR, Schmidt MI, et al. Homeostasis model assessment of insulin resistance (HOMA-IR) and metabolic syndrome at baseline of a multicentric Brazilian cohort: ELSA-Brasil study. Cad Saude Publica. 2020; 36 (8): e00072120. https://doi.org/10.1590/0102-311X00072120
Shrestha A, Pradhananga S. Holistic Approach in the Management of Nonalcoholic Fatty Liver Disease. Euroasian J Hepatogastroenterol. 2022; 12 (1): S51-S58. https://doi.org/10.5005/jp-journals-10018-1359
Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019; 156(5):1264-1281.e4. https://doi.org/10.1053/j.gastro.2018.12.036
Ampuero J, Pais R, Aller R, Gallego-Durán R, et al.; HEPAmet Registry. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. Clin Gastroenterol Hepatol. 2020; 18(1):216-225.e5. https://doi.org/10.1016/j.cgh.2019.05.051
Ferraioli G, Filice C, Castera L, Choi BI, et al. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: liver. Ultrasound Med Biol. 2015; 41(5):1161-79. https://doi.org/10.1016/j.ultrasmedbio.2015.03.007
Tobita H, Sato S, Miyake T, Ishihara S, et al. Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study. Curr Ther Res Clin Exp. 2017; 87: 13-19. https://doi.org/10.1016/j.curtheres.2017.07.002
Phrueksotsai S, Pinyopornpanish K, Euathrongchit J, Leerapun A, et al. The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2021; 36 (10): 2952-2959. https://doi.org/10.1111/jgh.15580
Ghosh A, Dutta K, Bhatt SP, Gupta R, et al. Dapagliflozin Improves Body Fat Patterning, and Hepatic and Pancreatic Fat in Patients With Type 2 Diabetes in North India. J Clin Endocrinol Metab. 2022; 107 (6): e2267-e2275. https://doi.org/10.1210/clinem/dgac138
Ng CH, Lin SY, Chin YH, et al. Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials. Endocr Pract. 2022; 28(2): 223-230. https://doi.org/10.1016/j.eprac.2021.09.013
Salah HM, Fudim M. Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease. Heart Fail Clin. 2022; 18(4):625-634. https://doi.org/10.1016/j.hfc.2022.03.011
Bica IC, Stoica RA, Salmen T, Janež A, et al. The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials. Medicina (Kaunas). 2023; 59 (6): 1136. https://doi.org/10.3390/medicina59061136
Jin Z, Yuan Y, Zheng C, Liu S, et al. Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials. J Diabetes Complications. 2023; 37 (8): 108558. https://doi.org/10.1016/j.jdiacomp.2023.108558
Jin Z, Yin R, Yuan Y, Zheng C, et al. Dapagliflozin ameliorates hepatic steatosis via suppressing LXRα-mediated synthesis of lipids and bile acids. Biochem Pharmacol. 2024; 223: 116167. https://doi.org/10.1016/j.bcp.2024.116167
Satyam SM, Bairy LK, Rehman A, Attia M, et al. Unlocking Synergistic Hepatoprotection: Dapagliflozin and Silymarin Combination Therapy Modulates Nuclear Erythroid 2-Related Factor 2/Heme Oxygenase-1 Pathway in Carbon Tetrachloride-Induced Hepatotoxicity in Wistar Rats. Biology (Basel). 2024;13(7):473. https://doi.org/10.3390/biology13070473
Caturano A, Galiero R, Loffredo G, Vetrano E, et al. Effects of a combination of empagliflozin plus metformin vs. metformin monotherapy on NAFLD progression in type 2 diabetes: the IMAGIN pilot study. Biomedicine. 2023; 11 (2): 322. https://doi.org/10.3390/biomedicines11020322
Esmaeili A, Pourahmad Azar R, Mohammad Hosseiniazar M, Hooshmand Gharabagh L. Empagliflozin add-on therapy is superior to metformin monotherapy in diabetic patients with NAFLD: An open-label, single-center, pilot clinical trial. J Gen Fam Med. 2024; 25 (6): 351-357. https://doi.org/10.1002/jgf2.723
Elseweidy MM, Ali AE, Hassanin SM, Mahmoud YK. Empagliflozin ameliorates liver fibrosis in NASH rat model via targeting hepatic NF-κB/SOX9/OPN signaling and osteocalcin level. Naunyn Schmiedebergs Arch Pharmacol. 2024; 397 (5): 3449-3459. https://doi.org/10.1007/s00210-023-02826-6
Cho HJ, Lee E, Kim SS, Cheong JY. SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea. Sci Rep. 2024; 14 (1): 9761. https://doi.org/10.1038/s41598-024-60133-3
Katsarou A, Tsioulos G, Kassi E, Chatzigeorgiou A. Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease. Hormones (Athens). 2024; 23 (4): 621-636. https://doi.org/10.1007/s42000-024-00588-1
Protas N, Kostitska I, Bielinskyi M. Hepatocentric approach to achieving compensation of diabetes mellitus in people with non-alcoholic steatohepatitis. Mìžnarodnij endokrinologìčnij žurnal. 2024; 20 (5): 375-382. https://doi.org/10.22141/2224-0721.20.5.2024.1423
Ong Lopez AMC, Pajimna JAT. Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis. Sci Rep. 2024; 14 (1): 2122. https://doi.org/10.1038/s41598-024-52603-5
This work is licensed under a Creative Commons Attribution 4.0 International License.
ISSN: 
